enGene Holdings Inc. Common Stock (ENGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) has a cash flow conversion efficiency ratio of -0.082x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.95 Million) by net assets ($230.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see enGene Holdings Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
enGene Holdings Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
enGene Holdings Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enGene Holdings Inc. Common Stock ranked by their cash flow conversion efficiency. See ENGN operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Master Drilling Group Ltd
JSE:MDI
|
-0.024x |
|
Sula Vineyards Limited
NSE:SULA
|
0.007x |
|
City Lodge Hotels Ltd
JSE:CLH
|
0.194x |
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
0.027x |
|
Lalin Property Public Company Limited
BK:LALIN
|
-0.017x |
|
Cloud Technologies S.A
WAR:CLD
|
0.037x |
|
Indo Kordsa Tbk
JK:BRAM
|
0.081x |
|
Mr. Blue Corporation
KQ:207760
|
-0.006x |
Annual Cash Flow Conversion Efficiency for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of enGene Holdings Inc. Common Stock from 2021 to 2025. View enGene Holdings Inc. Common Stock stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $167.71 Million | $-99.24 Million | -0.592x | -234.11% |
| 2024-10-31 | $272.61 Million | $-48.28 Million | -0.177x | +48.12% |
| 2023-10-31 | $72.49 Million | $-24.74 Million | -0.341x | -147.25% |
| 2022-10-31 | $127.42 Million | $-17.59 Million | -0.138x | -10.03% |
| 2021-10-31 | $127.39 Million | $-15.98 Million | -0.125x | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more